Abstract
AbstractEighteen patients with active rheumatoid arthritis were treated with gold sodium thiomalate (Myochrysine®) in this prospective clinical and metabolic study. Myochrysine and 195Au‐labeled Myochrysine were given at various times while the patients were hospitalized on a metabolic ward. Weekly gold excretion was determined from complete collection of urine and feces while in the hospital. Neutron activation analysis measured stable gold (197Au) content and radiometric analysis assayed 195Au activity. Weekly excretion of urine and total stable gold (total gold administered to date) and radiogold (current administered dose) did not correlate with clinical course or toxicity. There was a positive relationship between favorable course and fecal hypoexcretion of stable and radioactive gold, an observation requiring additional study and confirmation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
